tradingkey.logo
tradingkey.logo
Search

Kiniksa Pharmaceuticals International PLC

KNSA
Add to Watchlist
79.150USD
+15.615+24.58%
Close 07-28 16:00ETQuotes delayed by 15 min
6.04BMarket Cap
81.35P/E TTM

KNSA Income Statement

You can find the annual or quarterly income statement of Kiniksa Pharmaceuticals International PLC here for insights into the performance and operational efficiency of Kiniksa Pharmaceuticals International PLC.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q4
FY2019Q3
FY2019Q2
FY2019Q1
FY2018Q4
FY2018Q3
FY2018Q2
FY2018Q1
FY2017Q4
FY2017Q3
FY2017Q2
FY2017Q1
Total revenue
55.36%243.60M
55.51%214.27M
64.95%202.13M
61.17%180.85M
44.34%156.80M
72.54%137.78M
46.93%122.54M
67.37%112.21M
51.99%108.63M
65.18%79.86M
34.76%83.39M
-32.37%67.05M
164.99%71.47M
50.19%48.34M
230.14%61.88M
719.64%99.14M
250.10%26.97M
--32.19M
--18.75M
--12.10M
--7.70M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Revenue
55.36%243.60M
55.51%214.27M
64.95%202.13M
61.17%180.85M
44.34%156.80M
72.54%137.78M
46.93%122.54M
67.37%112.21M
51.99%108.63M
65.18%79.86M
34.76%83.39M
-32.37%67.05M
164.99%71.47M
50.19%48.34M
230.14%61.88M
719.64%99.14M
250.10%26.97M
--32.19M
--18.75M
--12.10M
--7.70M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Cost of revenue
26.71%23.57M
16.39%20.80M
17.04%20.95M
0.74%20.26M
50.97%18.60M
68.84%17.87M
86.73%17.90M
121.27%20.11M
60.05%12.32M
50.41%10.58M
42.83%9.58M
31.01%9.09M
53.09%7.70M
66.77%7.04M
73.52%6.71M
150.70%6.94M
103.93%5.03M
--4.22M
--3.87M
--2.77M
--2.47M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating expenses
58.38%216.41M
48.58%185.00M
28.57%182.36M
28.69%156.83M
25.65%136.64M
29.16%124.51M
70.24%141.84M
56.30%121.87M
45.72%108.75M
61.91%96.40M
49.21%83.31M
47.89%77.97M
61.04%74.63M
7.27%59.54M
1.75%55.84M
23.29%52.72M
-3.98%46.34M
12.63%55.51M
3.74%54.88M
-1.06%42.76M
51.47%48.26M
67.70%49.28M
62.36%52.90M
41.95%43.22M
-18.91%31.86M
-56.56%29.39M
-26.18%32.58M
16.39%30.45M
82.51%39.29M
314.00%67.65M
34.92%44.13M
60.99%26.16M
88.97%21.53M
223.69%16.34M
--32.71M
--16.25M
--11.39M
--5.05M
R&D expenses
118.09%40.90M
42.17%27.48M
-1.72%34.61M
-7.26%24.17M
-21.92%18.75M
-26.62%19.32M
75.62%35.22M
52.33%26.06M
1.05%24.02M
73.57%26.33M
39.35%20.05M
3.77%17.11M
72.25%23.77M
-27.12%15.17M
-47.54%14.39M
-14.30%16.48M
-42.38%13.80M
-27.42%20.82M
-26.65%27.43M
-38.78%19.24M
7.26%23.95M
37.23%28.68M
63.41%37.40M
42.72%31.42M
-27.63%22.32M
-64.73%20.90M
-36.64%22.89M
6.64%22.01M
79.35%30.85M
369.14%59.25M
20.68%36.12M
47.37%20.64M
85.50%17.20M
301.59%12.63M
--29.93M
--14.01M
--9.27M
--3.15M
Depreciation, depletion, and amortization
----
35.65%468.00K
16.75%467.00K
-3.76%384.00K
-16.74%358.00K
-25.97%345.00K
-25.93%400.00K
-33.83%399.00K
-28.57%430.00K
-21.81%466.00K
-10.30%540.00K
22.31%603.00K
-7.53%602.00K
-9.15%596.00K
-9.88%602.00K
-25.08%493.00K
-9.21%651.00K
110.26%656.00K
17.81%668.00K
1.39%658.00K
20.50%717.00K
-47.47%312.00K
0.18%567.00K
24.09%649.00K
17.13%595.00K
26.11%594.00K
122.83%566.00K
4258.33%523.00K
4133.33%508.00K
5787.50%471.00K
3075.00%254.00K
50.00%12.00K
100.00%12.00K
33.33%8.00K
--8.00K
--8.00K
--6.00K
--6.00K
Other operating expenses
68.01%88.07M
72.59%75.58M
45.32%70.03M
116.01%63.31M
74.65%52.42M
110.52%43.79M
184.49%48.19M
69.30%29.31M
114.60%30.01M
150.98%20.80M
125.19%16.94M
274.45%17.31M
280.88%13.99M
0.41%8.29M
800.84%7.52M
--4.62M
--3.67M
--8.25M
--835.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating profit
34.89%27.19M
120.52%29.27M
202.43%19.77M
348.72%24.02M
17330.77%20.16M
180.23%13.27M
-23925.93%-19.30M
11.61%-9.66M
96.29%-117.00K
-47.75%-16.54M
-98.66%81.00K
-123.54%-10.93M
83.72%-3.15M
51.99%-11.20M
116.74%6.05M
251.35%46.41M
52.24%-19.37M
52.68%-23.32M
31.70%-36.13M
29.04%-30.67M
-27.29%-40.55M
-67.70%-49.28M
-62.36%-52.90M
-41.95%-43.22M
18.91%-31.86M
56.56%-29.39M
26.18%-32.58M
-16.39%-30.45M
-82.51%-39.29M
-314.00%-67.65M
-34.92%-44.13M
-60.99%-26.16M
-88.97%-21.53M
-223.69%-16.34M
---32.71M
---16.25M
---11.39M
---5.05M
Net non-operating interest income (expenses)
Non-operating interest income
45.42%3.95M
48.89%3.41M
50.91%3.50M
27.64%3.14M
12.23%2.72M
1.19%2.29M
-2.07%2.32M
1.19%2.46M
26.42%2.42M
23.69%2.27M
198.36%2.37M
654.04%2.43M
1759.22%1.92M
5288.24%1.83M
931.17%794.00K
6340.00%322.00K
1616.67%103.00K
277.78%34.00K
156.67%77.00K
-89.80%5.00K
-97.74%6.00K
-98.86%9.00K
-97.35%30.00K
-96.46%49.00K
-84.57%266.00K
-56.38%789.00K
-34.57%1.13M
-14.55%1.39M
61.73%1.72M
493.11%1.81M
1198.50%1.73M
859.76%1.62M
596.73%1.07M
312.16%305.00K
--133.00K
--169.00K
--153.00K
--74.00K
Income before tax
36.14%31.14M
109.96%32.68M
237.05%23.27M
477.13%27.16M
892.93%22.88M
209.03%15.56M
-793.02%-16.98M
15.27%-7.20M
285.96%2.30M
-52.46%-14.28M
-64.19%2.45M
-118.19%-8.50M
93.57%-1.24M
59.79%-9.36M
118.97%6.84M
252.42%46.73M
52.49%-19.27M
52.74%-23.29M
31.80%-36.05M
28.97%-30.66M
-28.34%-40.55M
-72.30%-49.27M
-68.10%-52.87M
-48.55%-43.17M
15.90%-31.59M
56.56%-28.60M
25.84%-31.45M
-18.43%-29.06M
-83.59%-37.56M
-310.59%-65.84M
-30.17%-42.41M
-52.59%-24.54M
-82.05%-20.46M
-222.38%-16.04M
---32.58M
---16.08M
---11.24M
---4.97M
Income tax
65.99%8.37M
43.60%10.09M
212.10%9.07M
58.81%8.72M
-18.79%5.04M
104.96%7.03M
64.49%-8.09M
2.54%5.49M
138.32%6.21M
17.96%3.43M
-1057.44%-22.79M
103.02%5.36M
-2364.11%-16.21M
50.96%2.91M
753.05%2.38M
-150203.39%-177.36M
-29.39%716.00K
816.67%1.93M
-64.64%279.00K
-117.69%-118.00K
-82.74%1.01M
109.64%210.00K
128.03%789.00K
133.32%667.00K
1670.86%5.88M
-12717.65%-2.18M
101.16%346.00K
-1428.24%-2.00M
-85.15%-374.00K
67.92%-17.00K
218.52%172.00K
-156.86%-131.00K
-461.11%-202.00K
-60.61%-53.00K
--54.00K
---51.00K
---36.00K
---33.00K
Income after tax
27.70%22.77M
164.57%22.59M
259.75%14.20M
245.24%18.43M
556.29%17.83M
148.23%8.54M
-135.22%-8.89M
8.39%-12.69M
-126.10%-3.91M
-44.29%-17.70M
465.73%25.24M
-106.18%-13.86M
174.93%14.97M
51.33%-12.27M
112.28%4.46M
833.67%224.09M
51.93%-19.98M
49.05%-25.21M
32.29%-36.33M
30.32%-30.54M
-10.93%-41.56M
-87.30%-49.48M
-68.75%-53.66M
-62.01%-43.84M
-0.75%-37.47M
59.86%-26.42M
25.32%-31.80M
-10.87%-27.06M
-83.58%-37.19M
-311.84%-65.82M
-30.49%-42.58M
-52.26%-24.41M
-80.84%-20.26M
-223.46%-15.98M
---32.63M
---16.03M
---11.20M
---4.94M
Net income from continuous operations
42.62%25.43M
164.57%22.59M
259.75%14.20M
245.24%18.43M
556.29%17.83M
148.23%8.54M
-135.22%-8.89M
8.39%-12.69M
-126.10%-3.91M
-44.29%-17.70M
465.73%25.24M
-106.18%-13.86M
174.93%14.97M
51.33%-12.27M
112.28%4.46M
833.67%224.09M
51.93%-19.98M
49.05%-25.21M
32.29%-36.33M
30.32%-30.54M
-10.93%-41.56M
-87.30%-49.48M
-68.75%-53.66M
-62.01%-43.84M
-0.75%-37.47M
59.86%-26.42M
25.32%-31.80M
-10.87%-27.06M
-83.58%-37.19M
-311.84%-65.82M
-30.49%-42.58M
-52.26%-24.41M
-80.84%-20.26M
-223.46%-15.98M
---32.63M
---16.03M
---11.20M
---4.94M
Non-recurring net income
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
---69.00K
----
----
----
Other net gains and losses
--2.66M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
42.62%25.43M
164.57%22.59M
259.75%14.20M
245.24%18.43M
556.29%17.83M
148.23%8.54M
-135.22%-8.89M
8.39%-12.69M
-126.10%-3.91M
-44.29%-17.70M
465.73%25.24M
-106.18%-13.86M
174.93%14.97M
51.33%-12.27M
112.28%4.46M
833.67%224.09M
51.93%-19.98M
49.05%-25.21M
32.29%-36.33M
30.32%-30.54M
-10.93%-41.56M
-87.30%-49.48M
-68.75%-53.66M
-62.01%-43.84M
-0.75%-37.47M
59.86%-26.42M
25.32%-31.80M
-10.87%-27.06M
-83.58%-37.19M
-311.84%-65.82M
-30.21%-42.58M
-52.26%-24.41M
-80.84%-20.26M
-223.46%-15.98M
---32.70M
---16.03M
---11.20M
---4.94M
Net income attributable to common shareholders
42.62%25.43M
164.57%22.59M
259.75%14.20M
245.24%18.43M
556.29%17.83M
148.23%8.54M
-135.22%-8.89M
8.39%-12.69M
-126.10%-3.91M
-44.29%-17.70M
465.73%25.24M
-106.18%-13.86M
174.93%14.97M
51.33%-12.27M
112.28%4.46M
833.67%224.09M
51.93%-19.98M
49.05%-25.21M
32.29%-36.33M
30.32%-30.54M
-10.93%-41.56M
-87.30%-49.48M
-68.75%-53.66M
-62.01%-43.84M
-0.75%-37.47M
59.86%-26.42M
25.32%-31.80M
-10.87%-27.06M
-83.58%-37.19M
-311.84%-65.82M
-30.21%-42.58M
-52.26%-24.41M
-80.84%-20.26M
-223.46%-15.98M
---32.70M
---16.03M
---11.20M
---4.94M
Basic earnings per share
35.01%0.33
151.20%0.30
252.05%0.19
239.43%0.25
541.17%0.24
146.89%0.12
-134.27%-0.12
10.35%-0.18
-125.70%-0.06
-42.49%-0.25
459.63%0.36
-106.12%-0.20
174.26%0.21
51.76%-0.18
112.16%0.06
825.41%3.23
52.55%-0.29
49.69%-0.36
33.14%-0.53
33.07%-0.44
6.07%-0.61
-51.78%-0.72
-36.02%-0.79
-34.68%-0.66
5.23%-0.65
62.45%-0.48
32.54%-0.58
0.00%-0.49
-66.66%-0.68
-285.45%-1.27
-27.18%-0.86
-52.26%-0.49
-80.84%-0.41
-223.46%-0.33
---0.68
---0.32
---0.23
---0.10
Diluted earnings per share
33.29%0.30
140.77%0.27
241.19%0.17
230.17%0.23
515.68%0.23
144.74%0.11
-137.90%-0.12
10.35%-0.18
-126.33%-0.06
-42.49%-0.25
414.76%0.32
-106.21%-0.20
172.48%0.21
51.76%-0.18
111.96%0.06
814.03%3.18
52.55%-0.29
49.69%-0.36
33.14%-0.53
33.07%-0.44
6.07%-0.61
-51.78%-0.72
-36.02%-0.79
-34.68%-0.66
5.23%-0.65
62.45%-0.48
32.54%-0.58
0.00%-0.49
-66.66%-0.68
-285.45%-1.27
-27.18%-0.86
-52.26%-0.49
-80.84%-0.41
-223.46%-0.33
---0.68
---0.32
---0.23
---0.10
Dividend per share
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Kiniksa Pharmaceuticals International PLC's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing KNSA stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Kiniksa Pharmaceuticals International PLC's revenue at year end?

Kiniksa Pharmaceuticals International PLC reported 677.56M in revenue for fiscal year 2025, up from 423.24M in the previous year.

How much revenue did Kiniksa Pharmaceuticals International PLC report in the most recent quarter?

Kiniksa Pharmaceuticals International PLC reported 243.60M in revenue for the most recent quarter, an increase of 55.36% year over year.

What was Kiniksa Pharmaceuticals International PLC's net income for the year?

Kiniksa Pharmaceuticals International PLC posted 59.01M in net income for fiscal year 2025.

How much net income did Kiniksa Pharmaceuticals International PLC post in the last quarter?

Kiniksa Pharmaceuticals International PLC reported 25.43M in net income for the latest quarter。

What was Kiniksa Pharmaceuticals International PLC's annual operating profit?

Kiniksa Pharmaceuticals International PLC's operating income was 77.22M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.